{"id":645822,"date":"2023-04-06T14:56:01","date_gmt":"2023-04-06T14:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=645822"},"modified":"2023-04-06T14:56:01","modified_gmt":"2023-04-06T14:56:01","slug":"cataplexy-market-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-axome-therapeutics-suven-therapeutics-takeda-avel-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cataplexy-market-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-axome-therapeutics-suven-therapeutics-takeda-avel-therapeutics_645822.html","title":{"rendered":"Cataplexy Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Axome Therapeutics, Suven Therapeutics , Takeda , Avel Therapeutics"},"content":{"rendered":"
\n
\"Cataplexy<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Cataplexy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Cataplexy, historical and forecasted epidemiology as well as the Cataplexy market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/div>\n

DelveInsight’s “Cataplexy Market Insights, Epidemiology, and Market Forecast-2032<\/a><\/strong>” report delivers an in-depth understanding of the Cataplexy, historical and forecasted epidemiology as well as the Cataplexy market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/p>\n

 Cataplexy Overview<\/strong><\/p>\n

Cataplexy is a sudden and transient episode of muscle weakness accompanied by full conscious awareness, typically triggered by emotions such as laughing, crying, or terror.[1]<\/a> Cataplexy affects approximately 70% of people who have narcolepsy, and is caused by the autoimmune destruction of hypothalamic neurons that produce the neuropeptide hypocretin (also called orexin), which regulates arousal and has a role in the stabilization of the transition between wake and sleep states.]<\/a> Cataplexy without narcolepsy is rare and the cause is unknown.<\/p>\n

The term cataplexy originates from the Greek κατ\u03ac (kata, meaning “down”), and πλ\u1fc6ξις (pl\u0113xis, meaning “strike”), and it was first used around 1880 in German physiology literature to describe the phenomenon of tonic immobility also known as “playing possum” (in reference to the opossum’s behavior of feigning death when threatened). In the same year, the French neuropsychiatrist Jean-Baptiste Gélineau coined the term ‘narcolepsy’ and published some clinical reports that contain details about two patients who have similar conditions as the narcoleptic cases nowadays. Nevertheless, the onset reported by him was in adulthood as compared to the nowadays cases reported in childhood and adolescence. Even if he preferred the term ‘astasia’ instead of ‘cataplexy’ the case described by him remained iconic for the full narcoleptic syndrome<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 The Report Covers the Cataplexy Epidemiology Segmented by –<\/strong><\/p>\n